On March 19, 2021, Neos Therapeutics, Inc. completed its previously announced merger with Aytu BioScience, Inc. and Neutron Acquisition Sub, Inc., pursuant to the Agreement and Plan of Merger, dated as of December 10, 2020, by and among Parent, Merger Sub and Neos (the Merger Agreement). In accordance with the Merger, at the effective time, each of Alan Heller, Bryant Fong, Beth Hecht, Gerald McLaughlin, James Robinson, Greg Robitaille, John Schmid and Linda Szyper ceased serving as directors of the company, as the directors of Merger Sub as of immediately prior to the Effective Time became the directors of the company. Gerald McLaughlin was also ceased to be the president of the company. John Limongelli ceased to hold the positions of Senior Vice President, General Counsel and Corporate Secretary of the company.